secwatch.observer — SEC 8-K summary
======================================

Issuer:     Phio Pharmaceuticals Corp. (PHIO)
CIK:        0001533040
Form:       8-K
Filed at:   2026-04-08T23:59:59+00:00
Accession:  0001437749-26-011761
Event type: other_material
Sentiment:  neutral
Materiality: 0.65
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Phio Pharmaceuticals enters ATM offering agreement with H.C. Wainwright for up to $6.36M
--------------------------------------------------------------------------------

- Agreement allows sale of up to $6,360,000 of common stock via H.C. Wainwright as sales agent on an at-the-market basis.
- H.C. Wainwright receives a 3.0% commission on gross proceeds; company reimburses up to $75,000 in legal fees.
- No obligation to sell any shares; sales are made on Nasdaq Capital Market with T+1 settlement.
- Company provides customary indemnification to the sales agent under the agreement.
- The offering is registered under the company's existing S-3 shelf registration statement effective July 1, 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926011761/0001437749-26-011761-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1533040/000143774926011761/phio20260402_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-26-011761

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer